Core Insights - The U.S. losartan market is valued at approximately $245 million annually, with over 71 million prescriptions written each year, indicating a significant commercial opportunity for new formulations like Arbli [3][4]. Company Overview - Scienture Holdings, Inc. is focused on developing and commercializing novel specialty pharmaceutical products to meet unmet market needs, with a commitment to enhancing value for patients, physicians, and caregivers [11]. - Blink Rx LLC is a patient access platform that automates and improves the prescription journey, leading to better patient adherence and outcomes [2][12]. Product Details - Arbli is the first FDA-approved ready-to-use oral suspension formulation of losartan potassium, designed to provide a convenient alternative for patients who require or prefer liquid medication [5][6]. - The product is indicated for the treatment of hypertension in patients over six years old and for reducing the risk of stroke and treating diabetic nephropathy in certain patients with type 2 diabetes [7][14]. Strategic Collaboration - The partnership between Scienture and BlinkRx aims to enhance national access to Arbli, facilitating quicker therapy initiation and improved patient support throughout treatment [4][12]. - BlinkRx's platform is expected to increase the number of patients starting therapy by 52% and improve medication adherence by 40% [2].
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium